CCIA
STOK icon

Campbell & Co Investment Adviser’s Stoke Therapeutics STOK Stock Holding History

Campbell & Co Investment Adviser’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,049
Closed -$490K – 1345
2026
Q1 		$490K Buy
15,049
+2,054
+16% +$67.4K 0.03% 761
2025
Q4 		$412K Sell
12,995
-17,423
-57% -$524K 0.02% 890
2025
Q3 		$715K Buy
+30,418
New +$521K 0.05% 568

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Campbell & Co Investment Adviser's STOK Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Stoke Therapeutics (STOK) in Q2 2026, closing a stake of 15,049 shares — an estimated $490K sold.

Campbell & Co Investment Adviser first reported a position in STOK in Q3 2025 and held it in 3 quarters. The position peaked at $715K in Q3 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Stoke Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 15,049 Stoke Therapeutics shares in Q2 2026, an estimated $490K.
  • Campbell & Co Investment Adviser first reported a position in Stoke Therapeutics in Q3 2025 and held it in 3 quarters.
  • Campbell & Co Investment Adviser's Stoke Therapeutics position peaked at $715K in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.